Repository logo
  • English
  • 中文
  • Log In
    New user? Click here to register.Have you forgotten your password?
Repository logo
    Communities & Collections
    Research Outputs
    Fundings & Projects
    People
    Organizations
    Statistics
  • English
  • 中文
  • Log In
    New user? Click here to register.Have you forgotten your password?
  1. Home
  2. .TMU Publications / 北醫出版品(教師升等著作 / 教學實踐 / 學位論文)
  3. 今日北醫
  4. 2026年02月號
  5. 北醫大博士生以AI加速新藥研發,首獲Google博士生獎學金
 
  • Details
Options

北醫大博士生以AI加速新藥研發,首獲Google博士生獎學金

Type
other
Date Issued
2026-02-14
Author(s)
醫學科技學院
秘書處  
Subjects
今日北醫
Abstract
臺北醫學大學醫學科技學院「癌症生物學與藥物研發博士學位學程」博士生林偉德(Tony Eight Lin),在癌症生物學與藥物研發研究所許凱程教授團隊指導下,榮獲Google 2025年博士生獎學金。林偉德不僅是北醫大首位獲獎者,更是醫學背景大學第一人獲此殊榮,也展現北醫大培育跨域與雙棲人才的堅強實力。
URI
https://203.71.86.71/handle/123456789/8189
File(s)
Loading...
Thumbnail Image
Name

20260211.pdf

Size

231.99 KB

Format

Adobe PDF

Checksum

(MD5):42dc8cdf11c94733ebbe51552f2af25e

Copyright Notice

● The digital content on this platform is part of the Taipei Medical University Institutional Repository, featuring various academic works and outputs from the institution. It offers free access to academic research and public education for non-commercial use.

● Please use the content appropriately and within legal boundaries to respect copyright owners' rights. For commercial use, please obtain prior authorization from the copyright owner. Users must not use TMUIR for any illegal purposes.

● By utilising the platform, users are deemed to have fully accepted and understood all the regulations set out in this statement, relevant laws of the Republic of China, all international internet regulations, and usage conventions.

● TMUIR is committed to protecting the interests of copyright owners. If you believe that any material on this website infringes copyright, please contact our staff at libirtmu@gmail.com, and we will remove the work from the repository.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Cookie settings
  • Privacy policy
  • End User Agreement
  • Send Feedback